Epigenetic biomarkers in urological tumors: A systematic review

Cancer Letters

Volumn 342, Issue 2, 2014, Pages 264-274

  Jerónimo, Carmen ^a,b   Henrique, Rui ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

DNA methylation; Epigenetic based biomarkers; Genitourinary cancer; Histone modifications; MicroRNAs

Indexed keywords

AZACITIDINE; BCG VACCINE; BIOLOGICAL MARKER; CISPLATIN; MICRORNA; TUMOR MARKER;

BLADDER CANCER; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENETICS; GENE MUTATION; HISTONE MODIFICATION; HUMAN; KIDNEY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SYSTEMATIC REVIEW; TESTIS CANCER; TREATMENT RESPONSE; UROGENITAL TRACT CANCER;

EID: 84888198328     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.026     Document Type: Review

References (156)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide 2010, IARCPress, Lyon.
2. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61(2011):212-236.
3. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
4. V.T. DeVita, T.S. Lawrence, S.A. Rosenberg, R.A. Weinberg, R.A. DePinho, Cancer: Principles and Practice of Oncology 8th ed., Lippincott Williams & Wilkins, 2008.
5. Eble J.L., Sauter G., Epstein J.I., Sesterhenn I.A. World Health Organization., International Agency for Research on Cancer., Pathology and genetics of tumours of the urinary system and male genital organs 2004, IARC, Lyon.
6. Boyle P., Levin B. World cancer report 2008 2009, IARC Press, Lyon.
7. Brawer M.K. Screening for prostate cancer. Semin Surg Oncol 2000, 18:29-36.
8. Catalona W.J., Southwick P.C., Slawin K.M., Partin A.W., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., Walsh P.C., Scardino P.T., Lange P.H., Gasior G.H., Loveland K.G., Bray K.R. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000, 56:255-260.
9. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., Lieber M.M., Cespedes R.D., Atkins J.N., Lippman S.M., Carlin S.M., Ryan A., Szczepanek C.M., Crowley J.J., Coltman C.A. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003, 349:215-224.
10. Troyer D.A., Mubiru J., Leach R.J., Naylor S.L. Promise and challenge: markers of prostate cancer detection, diagnosis and prognosis. Dis. Markers 2004, 20:117-128.
11. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009, 374:239-249.
12. Brown A.L., Zietman A.L., Shipley W.U., Kaufman D.S. An organ-preserving approach to muscle-invading transitional cell cancer of the bladder. Hematol. Oncol. Clin. North Am. 2001, 15:345-358. vii.
13. Lopez-Beltran A., Carrasco J.C., Cheng L., Scarpelli M., Kirkali Z., Montironi R. 2009 update on the classification of renal epithelial tumors in adults. Int. J. Urol. 2009, 16:432-443.
14. Baldewijns M.M., van Vlodrop I.J., Schouten L.J., Soetekouw P.M., de Bruine A.P., van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim. Biophys. Acta 2008, 1785:133-155.
15. Lam J.S., Leppert J.T., Figlin R.A., Belldegrun A.S. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005, 66:1-9.
16. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma, Lancet 2009, 373:1119-1132.
17. Huyghe E., Matsuda T., Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J. Urol. 2003, 170:5-11.
18. Oosterhuis J.W., Looijenga L.H. Testicular germ-cell tumours in a broader perspective. Nat. Rev. Cancer 2005, 5:210-222.
19. Horwich A., Shipley J., Huddart R. Testicular germ-cell cancer. Lancet 2006, 367:754-765.
20. Veltri R.W., Makarov D.V. Nucleic acid-based marker approaches to urologic cancers. Urol. Oncol. 2006, 24:510-527.
21. Scelo G., Brennan P. The epidemiology of bladder and kidney cancer. Nat. Clin. Pract. Urol. 2007, 4:205-217.
22. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
23. Sidransky D. Emerging molecular markers of cancer. Nat. Rev. Cancer 2002, 2:210-219.
24. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4:143-153.
25. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
26. Goldberg A.D., Allis C.D., Bernstein E. Epigenetics: a landscape takes shape. Cell 2007, 128:635-638.
27. Lopez-Serra L., Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. British J. Cancer 2008, 98:1881-1885.
28. Vaissière T., Sawan C., Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mut. Res. 2008, 659:40-48.
29. Clark S.J., Melki J. DNA methylation and gene silencing in cancer: which is the guilty party?. Oncogene 2002, 21:5380-5387.
30. Doi A., Park I.H., Wen B., Murakami P., Aryee M.J., Irizarry R., Herb B., Ladd-Acosta C., Rho J., Loewer S., Miller J., Schlaeger T., Daley G.Q., Feinberg A.P. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 2009, 41:1350-1353.
31. Irizarry R.A., Ladd-Acosta C., Wen B., Wu Z., Montano C., Onyango P., Cui H., Gabo K., Rongione M., Webster M., Ji H., Potash J.B., Sabunciyan S., Feinberg A.P. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 2009, 41:178-186.
32. Scarano M.I., Strazzullo M., Matarazzo M.R., D'Esposito M. DNA methylation 40 years later: its role in human health and disease. J. Cell. Physiol. 2005, 204:21-35.
33. Attwood J.T., Yung R.L., Richardson B.C. DNA methylation and the regulation of gene transcription. Cell. Mol. Life Sci.: CMLS 2002, 59:241-257.
34. Tost J. DNA Methylation : Methods and Protocols 2nd ed 2009, Humana Press, New York.
35. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Gene. 2007, 8:286-298.
36. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
37. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
38. Coolen M.W., Stirzaker C., Song J.Z., Statham A.L., Kassir Z., Moreno C.S., Young A.N., Varma V., Speed T.P., Cowley M., Lacaze P., Kaplan W., Robinson M.D., Clark S.J. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat. Cell. Biol. 2010, 12:235-246.
39. Devaney J., Stirzaker C., Qu W., Song J.Z., Statham A.L., Patterson K.I., Horvath L.G., Tabor B., Coolen M.W., Hulf T., Kench J.G., Henshall S.M., Pe Benito R., Haynes A.M., Mayor R., Peinado M.A., Sutherland R.L., Clark S.J. Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiol. Biomarkers Prev. 2011, 20:148-159.
40. Stransky N., Vallot C., Reyal F., Bernard-Pierrot I., de Medina S.G., Segraves R., de Rycke Y., Elvin P., Cassidy A., Spraggon C., Graham A., Southgate J., Asselain B., Allory Y., Abbou C.C., Albertson D.G., Thiery J.P., Chopin D.K., Pinkel D., Radvanyi F. Regional copy number-independent deregulation of transcription in cancer. Nat. Genet. 2006, 38:1386-1396.
41. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
42. Jenuwein T., Allis C.D. Translating the histone code. Science (New York NY) 2001, 293:1074-1080.
43. Mellor J. The dynamics of chromatin remodeling at promoters. Mol. Cell 2005, 19:147-157.
44. Lennartsson A., Ekwall K. Histone modification patterns and epigenetic codes. Biochim. Biophys. Acta 2009, 1790:863-868.
45. Gibney E.R., Nolan C.M. Epigenetics and gene expression. Heredity 2010, 105:4-13.
46. Bhaumik S.R., Smith E., Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat. Struct. Mol. Biol. 2007, 14:1008-1016.
47. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Pérez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.A., Ahn N., Imhof A., Caldas C., Jenuwein T., Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
48. Guil S., Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int. J. Biochem. Cell Biol. 2009, 41:87-95.
49. Garzon R., Calin G.A., Croce C.M. MicroRNAs in Cancer. Ann. Rev. Med. 2009, 60:167-179.
50. Shenouda S.K., Alahari S.K. MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastasis Rev. 2009, 28:369-378.
51. Dudziec E., Miah S., Choudhry H.M., Owen H.C., Blizard S., Glover M., Hamdy F.C., Catto J.W. Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin. Cancer Res. 2011, 17:1287-1296.
52. Henrique R., Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur. Urol. 2004, 46:660-669. (discussion 669).
53. Jeronimo C., Usadel H., Henrique R., Oliveira J., Lopes C., Nelson W.G., Sidransky D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst. 2001, 93:1747-1752.
54. Harden S.V., Sanderson H., Goodman S.N., Partin A.A., Walsh P.C., Epstein J.I., Sidransky D. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J. Natl. Cancer Inst. 2003, 95:1634-1637.
55. Goessl C., Krause H., Muller M., Heicappell R., Schrader M., Sachsinger J., Miller K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000, 60:5941-5945.
56. Goessl C., Muller M., Heicappell R., Krause H., Straub B., Schrader M., Miller K. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001, 58:335-338.
57. Cairns P., Esteller M., Herman J.G., Schoenberg M., Jeronimo C., Sanchez-Cespedes M., Chow N.H., Grasso M., Wu L., Westra W.B., Sidransky D. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 2001, 7:2727-2730.
58. Jeronimo C., Usadel H., Henrique R., Silva C., Oliveira J., Lopes C., Sidransky D. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002, 60:1131-1135.
59. Gonzalgo M.L., Pavlovich C.P., Lee S.M., Nelson W.G. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 2003, 9:2673-2677.
60. Hoque M.O., Topaloglu O., Begum S., Henrique R., Rosenbaum E., Van Criekinge W., Westra W.H., Sidransky D. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol. 2005, 23:6569-6575.
61. Roupret M., Hupertan V., Yates D.R., Catto J.W., Rehman I., Meuth M., Ricci S., Lacave R., Cancel-Tassin G., de la Taille A., Rozet F., Cathelineau X., Vallancien G., Hamdy F.C., Cussenot O. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res. 2007, 13:1720-1725.
62. Ellinger J., Haan K., Heukamp L.C., Kahl P., Buttner R., Muller S.C., von Ruecker A., Bastian P.J. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008, 68:42-49.
63. Wu T., Giovannucci E., Welge J., Mallick P., Tang W.Y., Ho S.M. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br. J. Cancer 2011, 105:65-73.
64. Baden J., Green G., Painter J., Curtin K., Markiewicz J., Jones J., Astacio T., Canning S., Quijano J., Guinto W., Leibovich B.C., Nelson J.B., Vargo J., Wang Y., Wuxiong C. Multicenter evaluation of an investigational prostate cancer methylation assay. J. Urol. 2009, 182:1186-1193.
65. Baden J., Adams S., Astacio T., Jones J., Markiewicz J., Painter J., Trust C., Wang Y., Green G. Predicting Prostate Biopsy Result in Men With Prostate Specific Antigen 2.0 to 10.0 ng/ml Using an Investigational Prostate Cancer Methylation Assay. J. Urol. 2011, 186:2101-2106.
66. Ellinger J., Kahl P., von der Gathen J., Rogenhofer S., Heukamp L.C., Gutgemann I., Walter B., Hofstadter F., Buttner R., Muller S.C., Bastian P.J., von Ruecker A. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010, 70:61-69.
67. Schaefer A., Jung M., Mollenkopf H.J., Wagner I., Stephan C., Jentzmik F., Miller K., Lein M., Kristiansen G., Jung K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010, 126:1166-1176.
68. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105:10513-10518.
69. Bastian P.J. Re: poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. Eur. Urol. 2007, 51:1142-1143.
70. Ellinger J., Bastian P.J., Jurgan T., Biermann K., Kahl P., Heukamp L.C., Wernert N., Muller S.C., von Ruecker A. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008, 71:161-167.
71. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., Zahurak M., Piantadosi S., Walsh P.C., Bova G.S., De Marzo A.M., Isaacs W.B., Nelson W.G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004, 64:1975-1986.
72. Li L.C., Zhao H., Nakajima K., Oh B.R., Ribeiro Filho L.A., Carroll P., Dahiya R. Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J. Urol. 2001, 166:705-709.
73. Kang G.H., Lee S., Lee H.J., Hwang K.S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol. 2004, 202:233-240.
74. Jeronimo C., Henrique R., Hoque M.O., Mambo E., Ribeiro F.R., Varzim G., Oliveira J., Teixeira M.R., Lopes C., Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 2004, 10:8472-8478.
75. Jeronimo C., Henrique R., Hoque M.O., Ribeiro F.R., Oliveira J., Fonseca D., Teixeira M.R., Lopes C., Sidransky D. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin. Cancer Res. 2004, 10:4010-4014.
76. Henrique R., Jeronimo C., Teixeira M.R., Hoque M.O., Carvalho A.L., Pais I., Ribeiro F.R., Oliveira J., Lopes C., Sidransky D. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol. Cancer Res. 2006, 4:1-8.
77. Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Li L.C., Kawahara M., Nakagawa M., Kane C.J., Carroll P.R., Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res. 2005, 11:6582-6588.
78. Enokida H., Shiina H., Igawa M., Ogishima T., Kawakami T., Bassett W.W., Anast J.W., Li L.C., Urakami S., Terashima M., Verma M., Kawahara M., Nakagawa M., Kane C.J., Carroll P.R., Dahiya R. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004, 64:5956-5962.
79. Bastian P.J., Palapattu G.S., Lin X., Yegnasubramanian S., Mangold L.A., Trock B., Eisenberger M.A., Partin A.W., Nelson W.G. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 2005, 11:4037-4043.
80. Woodson K., O'Reilly K.J., Ward D.E., Walter J., Hanson J., Walk E.L., Tangrea J.A. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 2006, 1:183-186.
81. Cottrell S., Jung K., Kristiansen G., Eltze E., Semjonow A., Ittmann M., Hartmann A., Stamey T., Haefliger C., Weiss G. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J. Urol. 2007, 177:1753-1758.
82. Rosenbaum E., Hoque M.O., Cohen Y., Zahurak M., Eisenberger M.A., Epstein J.I., Partin A.W., Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res. 2005, 11:8321-8325.
83. Banez L.L., Sun L., van Leenders G.J., Wheeler T.M., Bangma C.H., Freedland S.J., Ittmann M.M., Lark A.L., Madden J.F., Hartman A., Weiss G., Castanos-Velez E. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J. Urol. 2010, 184:149-156.
84. Henrique R., Ribeiro F.R., Fonseca D., Hoque M.O., Carvalho A.L., Costa V.L., Pinto M., Oliveira J., Teixeira M.R., Sidransky D., Jeronimo C. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin. Cancer Res. 2007, 13:6122-6129.
85. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
86. Bianco-Miotto T., Chiam K., Buchanan G., Jindal S., Day T.K., Thomas M., Pickering M.A., O'Loughlin M.A., Ryan N.K., Raymond W.A., Horvath L.G., Kench J.G., Stricker P.D., Marshall V.R., Sutherland R.L., Henshall S.M., Gerald W.L., Scher H.I., Risbridger G.P., Clements J.A., Butler L.M., Tilley W.D., Horsfall D.J., Ricciardelli C. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol. Biomarkers Prev. 2010, 19:2611-2622.
87. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
88. Yu J., Rhodes D.R., Tomlins S.A., Cao X., Chen G., Mehra R., Wang X., Ghosh D., Shah R.B., Varambally S., Pienta K.J., Chinnaiyan A.M. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 2007, 67:10657-10663.
89. Kahl P., Gullotti L., Heukamp L.C., Wolf S., Friedrichs N., Vorreuther R., Solleder G., Bastian P.J., Ellinger J., Metzger E., Schule R., Buettner R. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006, 66:11341-11347.
90. Ozen M., Creighton C.J., Ozdemir M., Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27:1788-1793.
91. Ambs S., Prueitt R.L., Yi M., Hudson R.S., Howe T.M., Petrocca F., Wallace T.A., Liu C.G., Volinia S., Calin G.A., Yfantis H.G., Stephens R.M., Croce C.M. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008, 68:6162-6170.
92. Tong A.W., Fulgham P., Jay C., Chen P., Khalil I., Liu S., Senzer N., Eklund A.C., Han J., Nemunaitis J. MicroRNA profile analysis of human prostate cancers. Cancer Gene Therapy 2009, 16:206-216.
93. Hagman Z., Larne O., Edsjo A., Bjartell A., Ehrnstrom R.A., Ulmert D., Lilja H., Ceder Y. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int. J. Cancer 2010, 127:2768-2776.
94. Chan M.W., Chan L.W., Tang N.L., Tong J.H., Lo K.W., Lee T.L., Cheung H.Y., Wong W.S., Chan P.S., Lai F.M., To K.F. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 2002, 8:464-470.
95. Dulaimi E., Uzzo R.G., Greenberg R.E., Al-Saleem T., Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin. Cancer Res. 2004, 10:1887-1893.
96. Friedrich M.G., Weisenberger D.J., Cheng J.C., Chandrasoma S., Siegmund K.D., Gonzalgo M.L., Toma M.I., Huland H., Yoo C., Tsai Y.C., Nichols P.W., Bochner B.H., Jones P.A., Liang G. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 2004, 10:7457-7465.
97. Sathyanarayana U.G., Maruyama R., Padar A., Suzuki M., Bondaruk J., Sagalowsky A., Minna J.D., Frenkel E.P., Grossman H.B., Czerniak B., Gazdar A.F. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res. 2004, 64:1425-1430.
98. Urakami S., Shiina H., Enokida H., Kawakami T., Kawamoto K., Hirata H., Tanaka Y., Kikuno N., Nakagawa M., Igawa M., Dahiya R. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin. Cancer Res. 2006, 12:2109-2116.
99. Carmack A.J., Soloway M.S. The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology 2006, 67:3-8. discussion 8-10.
100. Renard I., Joniau S., van Cleynenbreugel B., Collette C., Naome C., Vlassenbroeck I., Nicolas H., de Leval J., Straub J., Van Criekinge W., Hamida W., Hellel M., Thomas A., de Leval L., Bierau K., Waltregny D. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur. Urol. 2010, 58:96-104.
101. Costa V.L., Henrique R., Danielsen S.A., Duarte-Pereira S., Eknaes M., Skotheim R.I., Rodrigues A., Magalhaes J.S., Oliveira J., Lothe R.A., Teixeira M.R., Jeronimo C., Lind G.E. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin. Cancer Res. 2010, 16:5842-5851.
102. Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., Gudas L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 2005, 11:8570-8576.
103. Hayami S., Kelly J.D., Cho H.S., Yoshimatsu M., Unoki M., Tsunoda T., Field H.I., Neal D.E., Yamaue H., Ponder B.A., Nakamura Y., Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 2011, 128:574-586.
104. Hanke M., Hoefig K., Merz H., Feller A.C., Kausch I., Jocham D., Warnecke J.M., Sczakiel G. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 2010, 28:655-661.
105. Maruyama R., Toyooka S., Toyooka K.O., Harada K., Virmani A.K., Zochbauer-Muller S., Farinas A.J., Vakar-Lopez F., Minna J.D., Sagalowsky A., Czerniak B., Gazdar A.F. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001, 61:8659-8663.
106. Yates D.R., Rehman I., Abbod M.F., Meuth M., Cross S.S., Linkens D.A., Hamdy F.C., Catto J.W. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 2007, 13:2046-2053.
107. Tada Y., Wada M., Taguchi K., Mochida Y., Kinugawa N., Tsuneyoshi M., Naito S., Kuwano M. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 2002, 62:4048-4053.
108. Aleman A., Cebrian V., Alvarez M., Lopez V., Orenes E., Lopez-Serra L., Algaba F., Bellmunt J., Lopez-Beltran A., Gonzalez-Peramato P., Cordon-Cardo C., Garcia J., del Muro J.G., Esteller M., Sanchez-Carbayo M. Identification of PMF1 methylation in association with bladder cancer progression. Clin. Cancer Res. 2008, 14:8236-8243.
109. Duarte-Pereira S., Paiva F., Costa V.L., Ramalho-Carvalho J., Savva-Bordalo J., Rodrigues A., Ribeiro F.R., Silva V.M., Oliveira J., Henrique R., Jeronimo C. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur. J. Cancer 2011, 47:1106-1114.
110. Dominguez G., Carballido J., Silva J., Silva J.M., Garcia J.M., Menendez J., Provencio M., Espana P., Bonilla F. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin. Cancer Res. 2002, 8:980-985.
111. Barbisan F., Mazzucchelli R., Santinelli A., Stramazzotti D., Scarpelli M., Lopez-Beltran A., Cheng L., Montironi R. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. Int. J. Immunopathol. Pharmacol. 2008, 21:615-623.
112. Cheung W.L., Albadine R., Chan T., Sharma R., Netto G.J. Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence. J. Urol. 2009, 181:1387-1392.
113. Schneider A.C., Heukamp L.C., Rogenhofer S., Fechner G., Bastian P.J., von Ruecker A., Muller S.C., Ellinger J. Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int. 2011.
114. Hinz S., Kempkensteffen C., Christoph F., Hoffmann M., Krause H., Schrader M., Schostak M., Miller K., Weikert S. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder. J. Cancer Res. Clin. Oncol. 2008, 134:331-336.
115. Wang H., Albadine R., Magheli A., Guzzo T.J., Ball M.W., Hinz S., Schoenberg M.P., Netto G.J., Gonzalgo M.L. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol. Oncol. 2011.
116. Dyrskjot L., Ostenfeld M.S., Bramsen J.B., Silahtaroglu A.N., Lamy P., Ramanathan R., Fristrup N., Jensen J.L., Andersen C.L., Zieger K., Kauppinen S., Ulhoi B.P., Kjems J., Borre M., Orntoft T.F. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009, 69:4851-4860.
117. Veerla S., Lindgren D., Kvist A., Frigyesi A., Staaf J., Persson H., Liedberg F., Chebil G., Gudjonsson S., Borg A., Mansson W., Rovira C., Hoglund M. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer 2009, 124:2236-2242.
118. Hoque M.O., Begum S., Topaloglu O., Jeronimo C., Mambo E., Westra W.H., Califano J.A., Sidransky D. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004, 64:5511-5517.
119. Gonzalgo M.L., Yegnasubramanian S., Yan G., Rogers C.G., Nicol T.L., Nelson W.G., Pavlovich C.P. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin. Cancer Res. 2004, 10:7276-7283.
120. Ibanez de Caceres I., Dulaimi E., Hoffman A.M., Al-Saleem T., Uzzo R.G., Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res. 2006, 66:5021-5028.
121. Dulaimi E., Ibanez de Caceres I., Uzzo R.G., Al-Saleem T., Greenberg R.E., Polascik T.J., Babb J.S., Grizzle W.E., Cairns P. Promoter hypermethylation profile of kidney cancer. Clin. Cancer Res. 2004, 10:3972-3979.
122. Costa V.L., Henrique R., Ribeiro F.R., Pinto M., Oliveira J., Lobo F., Teixeira M.R., Jeronimo C. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 2007, 7:133.
123. Jung M., Mollenkopf H.J., Grimm C., Wagner I., Albrecht M., Waller T., Pilarsky C., Johannsen M., Stephan C., Lehrach H., Nietfeld W., Rudel T., Jung K., Kristiansen G. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell Mol. Med. 2009, 13:3918-3928.
124. Petillo D., Kort E.J., Anema J., Furge K.A., Yang X.J., Teh B.T. MicroRNA profiling of human kidney cancer subtypes. Int. J. Oncol. 2009, 35:109-114.
125. Wulfken L.M., Moritz R., Ohlmann C., Holdenrieder S., Jung V., Becker F., Herrmann E., Walgenbach-Brunagel G., von Ruecker A., Muller S.C., Ellinger J. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011, 6:e25787.
126. Urakami S., Shiina H., Enokida H., Hirata H., Kawamoto K., Kawakami T., Kikuno N., Tanaka Y., Majid S., Nakagawa M., Igawa M., Dahiya R. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin. Cancer Res. 2006, 12:6989-6997.
127. Kim H.L., Seligson D., Liu X., Janzen N., Bui M.H., Yu H., Shi T., Belldegrun A.S., Horvath S., Figlin R.A. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J. Urol. 2005, 173:1496-1501.
128. Breault J.E., Shiina H., Igawa M., Ribeiro-Filho L.A., Deguchi M., Enokida H., Urakami S., Terashima M., Nakagawa M., Kane C.J., Carroll P.R., Dahiya R. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin. Cancer Res. 2005, 11:557-564.
129. Yamada D., Kikuchi S., Williams Y.N., Sakurai-Yageta M., Masuda M., Maruyama T., Tomita K., Gutmann D.H., Kakizoe T., Kitamura T., Kanai Y., Murakami Y. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int. J. Cancer 2006, 118:916-923.
130. Christoph F., Weikert S., Kempkensteffen C., Krause H., Schostak M., Kollermann J., Miller K., Schrader M. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin. Cancer Res. 2006, 12:5040-5046.
131. Peters I., Rehmet K., Wilke N., Kuczyk M.A., Hennenlotter J., Eilers T., Machtens S., Jonas U., Serth J. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol. Cancer 2007, 6:49.
132. Seligson D.B., Horvath S., McBrian M.A., Mah V., Yu H., Tze S., Wang Q., Chia D., Goodglick L., Kurdistani S.K. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 2009, 174:1619-1628.
133. Ellinger J., Kahl P., Mertens C., Rogenhofer S., Hauser S., Hartmann W., Bastian P.J., Buttner R., Muller S.C., von Ruecker A. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int. J. Cancer 2010, 127:2360-2366.
134. Minardi D., Lucarini G., Filosa A., Milanese G., Zizzi A., Di Primio R., Montironi R., Muzzonigro G. Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. J. Cell Mol. Med. 2009, 13:2115-2121.
135. Mosashvilli D., Kahl P., Mertens C., Holzapfel S., Rogenhofer S., Hauser S., Buttner R., Von Ruecker A., Muller S.C., Ellinger J. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 2010, 101:2664-2669.
136. Hinz S., Weikert S., Magheli A., Hoffmann M., Engers R., Miller K., Kempkensteffen C. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J. Urol. 2009, 182:2920-2925.
137. White N.M., Khella H.W., Grigull J., Adzovic S., Youssef Y.M., Honey R.J., Stewart R., Pace K.T., Bjarnason G.A., Jewett M.A., Evans A.J., Gabril M., Yousef G.M. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br. J. Cancer 2011, 105:1741-1749.
138. Ushida H., Kawakami T., Minami K., Chano T., Okabe H., Okada Y., Okamoto K. Methylation profile of DNA repetitive elements in human testicular germ cell tumor. Mol. Carcinog. 2011.
139. Peltomaki P. DNA methylation changes in human testicular cancer. Biochim. Biophys. Acta 1991, 1096:187-196.
140. Smiraglia D.J., Szymanska J., Kraggerud S.M., Lothe R.A., Peltomaki P., Plass C. Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene 2002, 21:3909-3916.
141. Smith-Sorensen B., Lind G.E., Skotheim R.I., Fossa S.D., Fodstad O., Stenwig A.E., Jakobsen K.S., Lothe R.A. Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. Oncogene 2002, 21:8878-8884.
142. Honorio S., Agathanggelou A., Wernert N., Rothe M., Maher E.R., Latif F. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene 2003, 22:461-466.
143. Lind G.E., Skotheim R.I., Fraga M.F., Abeler V.M., Esteller M., Lothe R.A. Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J. Pathol. 2006, 210:441-449.
144. Kempkensteffen C., Christoph F., Weikert S., Krause H., Kollermann J., Schostak M., Miller K., Schrader M. Epigenetic silencing of the putative tumor suppressor gene testisin in testicular germ cell tumors. J. Cancer Res. Clin. Oncol. 2006, 132:765-770.
145. Brait M., Maldonado L., Begum S., Loyo M., Wehle D., Tavora F.F., Looijenga L.H., Kowalski J., Zhang Z., Rosenbaum E., Halachmi S., Netto G.J., Hoque M.O. DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma. Br. J. Cancer 2011.
146. Kawakami T., Okamoto K., Ogawa O., Okada Y. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet 2004, 363:40-42.
147. Ellinger J., Albers P., Perabo F.G., Muller S.C., von Ruecker A., Bastian P.J. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J. Urol. 2009, 182:324-329.
148. Lambrot R., Kimmins S. Histone methylation is a critical regulator of the abnormal expression of POU5F1 and RASSF1A in testis cancer cell lines. Int. J. Androl. 2011, 34:110-123.
149. Gillis A.J., Stoop H.J., Hersmus R., Oosterhuis J.W., Sun Y., Chen C., Guenther S., Sherlock J., Veltman I., Baeten J., van der Spek P.J., de Alarcon P., Looijenga L.H. High-throughput microRNAome analysis in human germ cell tumours. J. Pathol. 2007, 213:319-328.
150. Looijenga L.H., Gillis A.J., Stoop H., Hersmus R., Oosterhuis J.W. Relevance of microRNAs in normal and malignant development, including human testicular germ cell tumours. Int. J. Androl. 2007, 30:304-314. (discussion 314-305).
151. Costa V.L., Henrique R., Danielsen S.A., Eknaes M., Skotheim R.I., Patrício P., Morais A., Oliveira J., Lothe R.A., Teixeira M.R., Lind G.E., Jeronimo C. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 2011, 6.
152. Weller M., Stupp R., Reifenberger G., Brandes A.A., van den Bent M.J., Wick W., Hegi M.E. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat. Rev. Neurol. 2010, 6:39-51.
153. Agundez M., Grau L., Palou J., Algaba F., Villavicencio H., Sanchez-Carbayo M. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours. Eur. Urol. 2011, 60:131-140.
154. Koul S., McKiernan J.M., Narayan G., Houldsworth J., Bacik J., Dobrzynski D.L., Assaad A.M., Mansukhani M., Reuter V.E., Bosl G.J., Chaganti R.S., Murty V.V. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol. Cancer 2004, 3:16.
155. Honecker F., Wermann H., Mayer F., Gillis A.J., Stoop H., van Gurp R.J., Oechsle K., Steyerberg E., Hartmann J.T., Dinjens W.N., Oosterhuis J.W., Bokemeyer C., Looijenga L.H. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J. Clin. Oncol. 2009, 27:2129-2136.
156. Wermann H., Stoop H., Gillis A.J., Honecker F., van Gurp R.J., Ammerpohl O., Richter J., Oosterhuis J.W., Bokemeyer C., Looijenga L.H. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J. Pathol. 2010, 221:433-442.